NEW YORK, July 2, 2018 /PRNewswire/ -- Neurotrope Inc.
(NASDAQ: NTRP) a clinical-stage biopharmaceutical company
developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease (AD), is announcing the
acceptance of a presentation at the Alzheimer's Association
International Conference 2018 (AAIC) being held in Chicago,
from July 22-26, 2018.
Title
|
Significant
Cognitive Improvement with Bryostatin for Advanced
Alzheimer's
|
|
Patients in the
Absence of Memantine (Poster presentation Abstract
#27295)
|
|
|
Developing Topics
Session:
|
P4-199:
|
Date/Time
|
Wednesday, July 25, 2018: 9:30
AM-4:15 PM
|
Location Hall
|
F1
- McCormick Place
|
"The primary mechanisms of action (MOAs) of bryostatin,
Neurotrope's lead compound to treat Alzheimer's disease (AD)
neurodegeneration, are synaptogenesis and anti-apoptosis: the
generation of new, mature synaptic connections and the prevention
of neuronal death. This has been demonstrated in pre-clinical
models because our target PKC epsilon activates synaptic growth
factors like BDNF, NGF and IGF-1. Our most recent comprehensive
data analyses, to be reported at AAIC 2018, have demonstrated that
advanced AD patients show improvement (> 6.0 points vs. placebo
and baseline) in the Severe Impairment Battery (SIB) even 30 days
after all drug dosing has been completed in patients not on
memantine. The data indicate that PKC's synaptogenesis efficacy
cannot occur when the NMDA receptor is blocked. Data from many
other laboratories over the years implicating NMDA in memory
processing could now take on new meaning from Neurotrope's clinical
results with bryostatin – in the absence of memantine. We are
excited to be presenting this new data at this prestigious
international forum" stated Dr. Daniel
Alkon, President and Chief Scientific Officer of
Neurotrope.
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combating AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
bryostatin as a potential treatment for Stroke, Traumatic Brain
Injury, and Fragile X Syndrome, Niemann-Pick Type C disease and
Rett Syndrome—rare genetic diseases for which only symptomatic
treatments are currently available. The FDA has granted Orphan Drug
Designation to Neurotrope for Bryostatin-1 as a treatment for
Fragile X Syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs in
AD.
Please visit www.neurotrope.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. These statements are subject
to the risk that further analyses of the Phase 2 data may lead to
different interpretations of the data than the analyses conducted
to date and/or may identify important implications of the Phase 2
data that are not reflected in these statements. Clinical trial
data are subject to differing interpretations, and regulatory
agencies, medical and scientific experts and others may not share
the Company's views of the Phase 2 data. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year
ended December 31, 2017, and on Form 10-Q for the quarter
ending March 31, 2018. The Company
does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Jeffrey Benison, Director of Corporate Communications
Neurotrope, Inc.
516.286.6099 (C) or 212.334.8709 (O)
jbenison@neurotrope.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-to-present-additional-phase-2-data-at-the-alzheimers-association-international-conference-aaic-2018-meeting-300675022.html
SOURCE Neurotrope, Inc.